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Abstract
The pathology of more than 40 human degenerative diseases is associated with fibrillar proteinaceous
deposits called amyloid. Collectively referred to as protein deposition diseases, many of these affect the
brain and the central nervous system. In many cases the amyloid deposits are extracellular and are found
associated with newly identified abundant extracellular chaperones (ECs). Evidence is discussed which
suggests an important regulatory role for ECs in amyloid formation and disposal in vivo. This is emerging
as an exciting field. A model is presented in which it is proposed that, under normal conditions, ECs
stabilize extracellular misfolded proteins by binding to them, and then guide them to specific receptors for
uptake and subsequent degradation. In this scenario, EC receptors are a critical part of a quality control
system which protects the brain against dangerously hydrophobic proteins/peptides. However, it also
appears possible that in the presence of a high molar excess of misfolded protein, such as might occur
during disease, the limited amounts of ECs available may actually exacerabate pathology. Further
advances in understanding of the mechanisms that control extracellular protein folding are likely to
identify new strategies for effective disease therapies.
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Extracellular Chaperones and Amyloids
Mark R Wilson, Justin J Yerbury, and Stephen Poon
School of Biological Sciences, University of Wollongong, Australia
ABSTRACT
The pathology of more than 40 human degenerative diseases is associated with
fibrillar proteinaceous deposits called amyloid. Collectively referred to as protein
deposition diseases, many of these affect the brain and the central nervous system. In
many cases the amyloid deposits are extracellular and are found associated with
newly identified abundant extracellular chaperones (ECs). Evidence is discussed
which suggests an important regulatory role for ECs in amyloid formation and
disposal in vivo. This is emerging as an exciting field. A model is presented in which
it is proposed that, under normal conditions, ECs stabilize extracellular misfolded
proteins by binding to them, and then guide them to specific receptors for uptake and
subsequent degradation. In this scenario, EC receptors are a critical part of a quality
control system which protects the brain against dangerously hydrophobic
proteins/peptides. However, it also appears possible that in the presence of a high
molar excess of misfolded protein, such as might occur during disease, the limited
amounts of ECs available may actually exacebate pathology. Further advances in
understanding of the mechanisms that control extracellular protein folding are likely
to identify new strategies for effective disease therapies.

Keywords: Extracellular chaperones, receptor-mediated endocytosis, amyloid,
protein quality control, aggregate toxicity, fibril formation

1.0 INTRODUCTION
The term "molecular chaperone" was first developed in the late 1970's when referring
to the ability of nucleoplasmin to inhibit inappropriate interactions between histones
and DNA (Laskey et al., 1978). The meaning of this term is continuing to evolve but
two key properties of molecular chaperones are (i) selective binding to non-native
protein conformations to form stable complexes, and (ii) inhibition of the irreversible
aggregation of non-native protein conformations (Fink 1999). Many molecular
chaperones maintain other proteins in "folding-competent" conformations, which are
returned to the native conformation by the involvement of other refolding chaperones.
Previous studies have overwhelmingly focussed on intracellular molecular chaperones
and their roles in protein folding within the cell. The discoveries that a range of
serious human diseases are related to protein aggregation phenomena, and that
molecular chaperones affect these processes, has led to a recent explosion of research
in this area. The pathology of more than 40 human degenerative diseases is associated
with the deposition of fibrillar proteinaceous aggregates called amyloid. Collectively
referred to as protein deposition diseases, these include various sporadic (e.g.
Alzheimer’s (AD) and Parkinson’s (PD) diseases), familial, and transmissible
degenerative disorders (e.g. spongiform encephalopathies such as Creutzfeldt-Jakob
disease (CJD)), many of which affect, amongst other tissues and organs, the brain and
the central nervous system (CNS). In many cases, molecular chaperones have been
found physically associated with amyloid deposits, although the reason for this
association remains to be established.
It is notable that many neurodegenerative disorders are associated with extracellular
amyloid deposits. It has only recently become apparent that extracellular counterparts
to the intracellular molecular chaperones exist. These proteins share functional
characteristics with the small heat shock proteins in that they are able to efficiently
stabilize misfolded proteins to prevent them aggregating but are not capable of
independently refolding such proteins. Strikingly, in all cases tested, at least one or
more of these "extracellular chaperones" (ECs) are associated with amyloid deposits
found outside cells (Table 1). The role of these abundant ECs in the formation of
amyloid deposits in vivo is emerging as an exciting field. In this chapter, we first
briefly discuss what is understood about the molecular basis of amyloid formation
before examining the available evidence that ECs influence this process and
discussing the potential roles of ECs in amyloid formation and disposal in vivo.
2.0 AMYLOIDS AND THE BRAIN
2.1 Amyloid formation
The hallmark of a wide range of debilitating and incurable human pathologies is the
abnormal presence of extracellular deposits in a variety of organs and tissues,
including the brain and CNS (e.g. AD, CJD), peripheral organs such as the heart, liver,
and spleen (e.g. systemic amyloidoses), and skeletal tissues and joints (e.g.
haemodialysis-related amyloidosis). The extent of in vivo deposition can vary
significantly depending on the disease state as well as the location of the deposits. For
instance, deposits associated with neurodegenerative diseases of the brain typically
weigh as little as a few grams whilst systemic deposits can accumulate to quantities of
as much as several kilograms (Pepys 1995).
Amyloid fibrils arise when a specific protein or protein fragment converts from an
otherwise soluble form into insoluble filamentous aggregates. Key fibril-forming

proteins associated with amyloid deposits and diseases have included full-length
globular proteins, bioactive peptides (e.g. calcitonin), and fragments of whole proteins
produced by specific cellular processing (e.g. the processing of amyloid precursor
protein (APP) to yield Aβ) or by natural degradation. In recent years, it has become
apparent that the self-assembly of proteins into amyloid fibrils is not restricted to the
relatively small number of proteins associated with the protein deposition diseases.
An increasing body of evidence points to this phenomenon as being a generic
property of polypeptide chains, suggesting that most, if not all, proteins have the
potential to form amyloid fibrils if exposed to appropriate conditions (Dobson 1999).
What triggers the in vivo conversion of a protein from its native state into amyloid
fibrils is not known, however, several important determinants of the fibrillation of
proteins have been identified, including hydrophobicity and net charge (Chiti and
Dobson 2006). At present, a detailed understanding of the mechanism for the
transition from soluble precursors to mature amyloid fibrils is lacking. Despite this, it
seems that the aggregation behaviours of various amyloid-forming peptides and
proteins are strikingly similar. Often described as a hierarchical process involving
multiple stages of assembly, the kinetics of amyloid formation (as measured by ThT
fluorescence or light scattering) is generally characterized by an initial ‘lag’ or
nucleation phase, followed by a rapid exponential ‘growth’ or polymerization phase
(Jarrett and Lansbury 1993), and lastly, by a plateau phase in which no further
polymerization occurs (Fig. (1)).
The lag (or nucleation) phase is defined as the time required for the formation of the
soluble (prefibrillar) oligomers or nuclei. This phase begins with the destabilization
and partial unfolding of the native protein, leading to the formation of an ensemble of
intermediately folded species. In vitro studies show that structural perturbation
leading to protein unfolding can be achieved by exposing the native protein to one or
more chaotropic conditions, including elevated temperature, low pH, oxidative stress,
molecular crowding, and protease-mediated degradation (Kelly 1998). In vivo, the
fate of the proteins within the ensemble of partially unfolded intermediates depends
on the environmental conditions present at the time of their existence. Some proteins
may be re-folded, whilst others may be degraded. A subset of proteins within this
ensemble will undergo non-ordered aggregation to form nuclei. When viewed by
transmission electron (TEM) or atomic-force (AFM) microscopy, these species may
appear as small beads that are linked together to produce what are often described as
amorphous aggregates or micelles (Yong et al., 2002). The nucleation phase, which
constitutes the rate-limiting step in amyloid formation, is relatively slow, due largely
to unfavourable protein association equilibria rather than to intrinsically slow
association rates (Jarrett and Lansbury 1993). After nucleation and immediately
preceding the polymerization phase, the nuclei transform into an ensemble of various
assemblies called protofibrils that exhibit increased levels of complexity and order.
During the polymerization phase, these protofibrils rapidly grow via the addition of
either monomers or oligomers that are formed after the initiation of the aggregation
process, leading to the formation of well-ordered protofilaments. The lateral
association of such protofilaments, accompanied by minor structural reorganization, is
thought to give rise to the formation of mature amyloid fibrils (van Gestel and de
Leeuw 2007).
Regardless of their individual protein composition, the molecular architecture of all
amyloid fibrils shares some striking similarities. Despite a lack of information

detailing the structure of amyloid fibrils at the atomic level, techniques such as X-ray
fibre diffraction, solid-state NMR, and cryoelectron microscopy have given insights
into how proteins pack together to form such highly ordered structures. Typically,
amyloid fibrils exist as long, unbranched, but often twisted structures that are 6-12
nanometres in diameter, bearing a characteristic ‘cross-β’ X-ray fibre diffraction
pattern (Sunde and Blake 1997). Each fibril is usually comprised, within its core
structure, of two to six ‘protofilaments’ that wind around each other to form
supercoiled rope-like structures. Protofilaments are believed to be principally
stabilized by intra- and intermolecular interactions (e.g. hydrogen bonds) and are
composed of β-sheets whose strands lie perpendicular to the long axis of the fibril
(Serpell 2000; Serpell et al., 2000).
2.2 Amyloid pathology in the brain
Protein deposition diseases are typically characterized by protein aggregates in
specific regions of the brain, neuronal death and brain function decline. In the case of
AD, pathological symptoms include both large anatomical and microscopic changes,
and are generally characterized by gross diffuse atrophy, primarily in the frontal,
temporal and parietal regions of the cortex, and extensive neuronal loss. Microscopic
features, commonly detected by histological staining procedures, include extracellular
amyloid plaques and intracellular neurofibrillary tangles (Gorevic et al., 1986).
Pathological features of PD, on the other hand, include the accumulation of Lewy
bodies within the cytoplasm of pigmented neurons of the cerebral cortex. Yet, for
CJD, no obvious gross pathology, besides neuronal loss and gliosis, is ever observed
due to the short course of the lethal disease. Despite advances in understanding of the
pathological basis of the various amyloid-related neuropathies, the actual cause/s of
disease remains undetermined and are the subject of intense investigation. Numerous
theories have been advanced to account for the pathology of amyloid diseases. Many
of these theories particularly focus on the toxic nature of amyloids and how this
relates to neuronal loss in the brain (reviewed in (Stefani and Dobson 2003)).
One theory proposes that disease pathology might simply be attributed to the shear
bulk of deposited material present in the affected organs and tissues, such as the brain.
It suggests that the extensive accumulation of amyloid deposits causes physical
disruption to the cellular architecture, subsequently leading to organ dysfunction.
Another theory suggests that the formation of pores or channels in neuronal cells by
oligomeric species formed from the self-association of partially unfolded proteins
may be a critical determinant of amyloid-related neuropathy. Consistent with this idea,
atomic force microscopy (AFM) has shown that Aβ, the primary constituent of senile
plaques, can form pore-like structures in vitro (Chromy et al., 2003; Lashuel et al.,
2003). In addition, ion flux data indicate that synthetic Aβ can form cation-selective
channels across model membranes, leading to increased membrane permeability,
disruption of calcium homeostasis and associated cellular degeneration (Arispe et al.,
1993). Similar pore forming activity has also been reported for amylin, the major
component of type-II diabetes-associated islet β-amyloid (Mirzabekov et al., 1996)
and Cu/Zn superoxide dismutase (SOD1), which is associated with amyotrophic
lateral sclerosis (ALS) (Chung et al., 2003).
A more recent and widely accepted theory proposes that soluble, inherently toxic
species are the primary cause of pathogenesis in disorders such as AD. Until recently,
neuronal cell death was attributed to the presence of mature fibrils, the most common

form of proteinaceous aggregates present in pathological deposits. Yet, an increasing
quantity of data suggests that the highly toxic species are in fact the pre-fibrillar
structures (e.g. oligomers and protofibrils), rather than the mature fibrils into which
they develop. Exemplifying this, small, soluble and diffusible Aβ oligomers (often
refered to as amyloid β-derived diffusible ligands or ADDLs) have been shown to be
highly toxic to cultured neuronal cells, even at nanomolar concentrations (Dahlgren et
al., 2002). The demonstration that these species are, in addition to being highly
cytotoxic, readily diffusible throughout the brain may explain why neuronal loss is
commonly observed at sites distant from those of the amyloid deposits. By proposing
that the primary toxic species are the early aggregates, this theory also provides a
plausible explanation for the lack of correlation between the extent of deposition of
mature fibrils in the form of amyloid plaques in the diseased brain and the severity of
clinical symptoms (Katzman et al., 1988).
Protein aggregation is often accompanied by the production of reactive oxygen
species (ROS), although the reason/s for this is not entirely understood. There is
evidence to indicate that oxidative stress, arising from the ageing process or from the
production of ROS, contributes to disease pathology. The observation that Aβ
deposition in the brain is positively correlated with regions of oxidative stress and
neurodegeneration supports this notion (Hensley et al., 1995). Lending further support
is the demonstration that antioxidants such as lipoic acid and resveratrol can protect
cells against aggregate-mediated toxicity (Savaskan et al., 2003; Jesudason et al.,
2005). Disease pathology is believed to arise because oxidative stress reduces the
expression levels and activity of the multicatalytic proteosome (MCP), which is
normally responsible for ubiquitin ATP-dependent degradation of aberrant protein
structures. The reduction of available MCP leads to the accumulation of oxidized and
damaged proteins at levels that are sufficient to induce neuronal cell death (Keller et
al., 2000).
2.3 Potential control mechanisms?
Inside cells the collective functions of chaperones, the ubiquitin-proteasome system
and lysosome-mediated autophagy is usually sufficient to prevent accumulation of
misfolded proteins. However, under certain conditions the capacity of this quality
control system is exceeded and protein aggregates accumulate (Muchowski and
Wacker 2005). Intracellular levels of molecular chaperones in the brain are thought to
be lowered with increasing age (Hay et al., 2004), which may contribute to the often
late onset of protein deposition diseases. Overexpression of intracellular heat shock
proteins (HSPs) in the nematode Caenorhabditis elegans promotes longevity, and in
the same system a reduction in the level of heat shock factors (transcriptional
activators) and thus HSPs shortens lifespan (Westerheide and Morimoto 2005). These
results suggest that intracellular chaperones are vital in the continuous fight against
misfolded protein aggregation and amyloid formation. As a corollary, it appears likely
that in diseases involving extracellular protein deposition, the extracellular processes
that normally operate to inhibit protein aggregation and to clear protein deposits may
be impaired - they are certainly overwhelmed. This is supported by the observation
that, apart from people carrying mutations that result in increased production of Aβ
(e.g. presenilins or APP genes), the rate of formation of Aβ does not increase with age
(Deane et al., 2004) but its normally efficient removal from the cerebrospinal fluid
(CSF) is slowed in aged humans (Zlokovic et al., 2000).

Understanding of the mechanisms controlling protein folding in extracellular spaces,
especially in the CNS, is in its infancy. However, there is evidence to suggest that
there are such mechanisms. For example, although CSF is regularly released into the
venous system through the arachnoid villi, the half lives of proteins in the CSF differ
from protein to protein, and even differ between various proteolytic fragments of the
same original protein (Savage et al., 1998), suggesting a selective mechanism of
removal. Recently it was proposed that there is an extracellular protein quality control
system consisting of abundant secreted ECs that recognise and facilitate the disposal
of non-native or dangerously hydrophobic proteins via receptor-mediated cell uptake
(Yerbury et al., 2005). These proteins may patrol the CNS for misfolded proteins and
under normal conditions prevent their aggregation and mediate their clearance.
3.0 EXTRACELLULAR CHAPERONES
In the extracellular environment, protein concentrations may be high, as in human
plasma (about 70 mg/ml), or lower such as in human CSF (120-640 µg/ml) (Williams
and Marshall 2001). Exposure to stresses capable of inducing protein unfolding is
common (e.g. sheer stress in extracellular fluids, hyperthermia, oxidative stress,
transient pH fluctuations), and ATP is 1000 times less abundant than inside cells
(Farias et al., 2005). In the event of a large-scale presentation of extracellular nonnative protein(s), such as might occur during amyloid disease, only ATP-independent,
physically abundant extracellular chaperone(s) could reasonably be expected to
provide an effective line of defense. Intracellular chaperones (e.g. Hsp70, Hsp90) are
present in human plasma and CSF and are associated with cell surfaces (in particular
cancer cells); they are thought to be released from dead or dying cells. Many
potentially important extracellular roles have been proposed for these chaperones,
such as cancer cell invasiveness (Eustace et al., 2004), immune presentation (Becker
et al., 2002) and signaling (Whittall et al., 2006). However, these “normally
intracellular” chaperones are present extracellularly at very low (ng/ml) levels and
require ATP to carry out protein refolding. Thus, the capacity of the low levels of
Hsp70 and similar chaperones present extracellularly would be quickly exceeded.
Therefore, it is far more likely that bulk processing of non-native proteins is dealt
with by much more abundant proteins with chaperone properties, herafter referred to
as extracellular chaperones (ECs), which have only recently been identified.
Four secreted glycoproteins, clusterin (Humphreys et al., 1999), haptoglobin (Yerbury
et al., 2005), α2-macroglobulin (French et al., 2007) and serum amyloid P component
(SAP) (Coker et al., 2000), have been shown to exhibit chaperone properties in vitro.
These four proteins share some notable similarities. All four are secreted
glycoproteins widely distributed in most physiological fluids, including plasma and
CSF (Barrett 1981; Baltz et al., 1982; Bowman and Kurosky 1982; Humphreys et al.,
1999). Moreover, all bind to a broad range of ligands (Barrett 1981; Capiau et al.,
1986; Katnik et al., 1987; Aruga et al., 1993; Katnik et al., 1993; Zahedi 1996;
Ashton et al., 1997; Langlois et al., 1997; Zahedi 1997; Kurdowska et al., 2000;
Wilson and Easterbrook-Smith 2000; Kimura et al., 2001; Sen and Heegaard 2002)
and have been found associated with clinical amyloid deposits in vivo (Table (1))
(Powers et al., 1981; Baltz et al., 1982; Van Gool et al., 1993; McHattie and Edington
1999; Calero et al., 2000). In addition all have been shown to mediate receptormediated endocytosis of ligands (see below). In terms of the chaperone action,
clusterin is currently the best characterized.

3.1 Clusterin
Clusterin is a protein secreted from many different cell types that is found in human
plasma, CSF and seminal fluid at concentrations of approximately 100, 2, and 1000
µg/ml (Fritz et al., 1983; Murphy et al., 1988; Choi-Miura et al., 1992), respectively.
It can also transit from the cell secretory system to the cytosol during certain stress
conditions, although the reasons why this occurs remain to be established (Nizard et
al., 2007). Clusterin mRNA is nearly ubiquitous in animal tissues, being found in
locales as diverse as the rat prostate gland and quail neuroretinal cells. The expression
of clusterin is increased in a wide variety of models of stress and disease, including
withdrawal of growth factors and exposure to noxious agents (Jenne and Tschopp
1992). The clusterin promoter contains a highly conserved 14 bp element which is
recognized by the transcriptional regulator heat shock factor 1 (HSF1) (Michel et al.,
1997). HSF1 activates expression of heat shock proteins (which protect cells from
stresses) and clusterin (Michel et al., 1997). Across different mammalian species, the
amino acid sequence of the protein is maintained at the level of 70-80% (Jenne and
Tschopp 1992). Clusterin is encoded by a single gene and the translated product is
internally cleaved to produce its α and β subunits prior to secretion from the cell.
Matrix-assisted laser desorption ionization mass spectrometry has identified two
primary forms of human plasma clusterin at about 58 kDa and 63.5 kDa, which
probably represent different glycoforms. The exclusively N-linked glycosylation is
variable in nature and extent, ranging from 17-27% (by weight) (Kapron et al., 1997).
The function of the glycosylation is unknown, although it may be involved in
recognition by cell surface receptors (Stewart et al., 2007). Probably because of the
substantive and variable glycosylation, when analysed by SDS PAGE, clusterin
migrates as a broad band corresponding in position to a mass of 70-80 kDa. In
aqueous solution at physiological pH, clusterin exists in a range of oligomeric forms;
mildly acidic pH favours partial dissociation of oligomers into individual α-β
heterodimers (Hochgrebe et al., 2000). Current insights into clusterin structure are
largely reliant upon predictions based on sequence analyses, which suggest that the
protein has significant contiguous regions of disordered (possibly molten globule)
conformation that separate other regions of well-defined secondary structure, such as
amphipathic α-helical regions and coiled-coil α-helices (Dunker et al., 2001; Dunker
et al., 2002). On this basis, clusterin has been categorized as an intrinsically
disordered protein (Dunker et al., 2001; Dunker et al., 2002). The high level of
disorder, variable glycosylation and tendency to form oligomers have so far limited
attempts to structurally characterise clusterin by approaches such as NMR, X-ray
crystallography and mass spectrometry.
Recent studies have demonstrated that clusterin has chaperone activity with a potent
ability to influence the amorphous and fibrillar aggregation of many different proteins.
Clusterin potently inhibits stress-induced protein aggregation by ATP-independent
binding to exposed regions of hydrophobicity on non-native proteins to form soluble,
high molecular weight complexes (Humphreys et al., 1999; Poon et al., 2000;
Yerbury et al., 2007). Immunoaffinity depletion of clusterin from human plasma
renders proteins in this fluid more susceptible to aggregation and precipitation (Poon
et al., 2002). Clusterin lacks the ability to independently refold heat-stressed, nonnative enzymes but, like the small heat shock proteins, is able to preserve heatinactivated enzymes in a state competent for subsequent ATP-dependent refolding by
Hsc70 (Poon et al., 2000). However, because there is no currently known abundant

refolding-competent EC, the physiological significance of this remains uncertain.
During amorphous aggregation of proteins, clusterin appears to interact with slowly
aggregating species on the off-folding pathway.
By complexing with misfolded extracellular proteins, ECs like clusterin may mediate
their cellular uptake and degradation (Yerbury et al., 2005). Clusterin has long been
known to interact with the cell surface receptor megalin (LRP2) and to complex with
Aβ to mediate its uptake by megalin and subsequent degradation (Hammad et al.,
1997). It also interacts with other members of the low density lipoprotein (LDL)
receptor family - it binds to chicken LR8 and an LDLR-related protein (Mahon et al.,
1999), and uptake of clusterin-leptin complexes by apoER2 and VLDLR has been
proposed to facilitate leptin clearance (Bajari et al., 2003). Furthermore, clusterin and
LRP1/megalin have been implicated in the clearance of cellular debris by nonprofessional phagocytes (Bartl et al., 2001).
3.2 Haptoglobin
Haptoglobin (Hp) is a secreted acidic glycoprotein (20% of its total mass is N-linked
carbohydrate (Bowman and Kurosky 1982)) produced mainly in the liver and found
in most body fluids of humans and other mammals. Normally, it is present in human
plasma at 300-2000 µg/ml (Bowman and Kurosky 1982) and CSF at 0.5-2 µg/ml
(Sobek and Adam 2003). However, the levels of Hp in human plasma are increased
up to 8-fold during inflammation, various infections, trauma, tissue damage and in
association with neoplasia, leading to it being designated as an "acute phase protein"
(Bowman and Kurosky 1982; Dobryszycka 1997). Hp is encoded by a single gene;
uniquely, in humans, there are two principal alleles (Hp1 and Hp2), which results in
individual humans expressing one of three major Hp phenotypes (Hp 1-1, Hp 2-1, Hp
2-2). In all cases, Hp can be represented as a multimer of an αβ subunit. In its
simplest form (Hp 1-1), Hp consists of a disulfide-linked (α1)2β2 structure (~100 kDa).
However, in Hp 2-1 and Hp 2-2, an additional cysteine residue in the α2 chain allows
the formation of a complex series of various sized disulfide-linked αβ polymers (~100
to ~500 kDa).
Hp binds with extremely high affinity to hemoglobin (Hb) (KD ~ 10-15 M; (Bowman
and Kurosky 1982)). Formation of the Hp-Hb complex inhibits Hb-mediated
generation of lipid peroxides and hydroxyl radical, which is thought to occur in areas
of inflammation (Dobryszycka 1997). Although it was previously thought that Hp
cleared the body of vascular Hb released from damaged red blood cells, recent work
has shown that the ablation of Hp expression in mice had no significant effect on Hb
clearance following experimentally induced severe hemolysis. Nevertheless, the Hp
knock-out mice suffered substantially greater mortality under these conditions, which
was attributed to greater oxidative stress (Lim et al., 1998). Therefore, it appears
likely that Hp exerts an important anti-inflammatory action in vivo by inhibiting
oxidative damage mediated by free Hb (Lim 2001). A variety of other putative
functions have also been ascribed to Hp. It has been implicated in immune regulation
(Louagie et al., 1993), shown to inhibit cathepsin B activity (Snellman and Sylven
1967) and to have pro-angiogenic effects (Cid et al., 1993). Binding of Hp to human
neutrophils has been reported to inhibit respiratory burst activity (Oh et al., 1990). In
addition, neutrophils have been shown to take up exogenous Hp and store it within
cytoplasmic granules - they subsequently secrete it into the local extracellular
environment in response to a variety of pro-inflammatory stimuli (e.g. yeast, TNFα,

or the chemotactic peptide fMLP (Wagner et al., 1996; Berkova et al., 1999)). Thus,
the available evidence indicates that Hp is likely to play an important role in
suppressing inflammatory responses.
Human Hp specifically inhibits the precipitation of a wide variety of proteins induced
by a range of stresses (Pavlicek and Ettrich 1999; Yerbury et al., 2005). All three
human Hp phenotypes exert this chaperone action, although at equivalent mass
concentrations, at least for one substrate protein tested, Hp1-1 was the most efficient.
Like clusterin, Hp forms stable, soluble high molecular weight complexes with
misfolded proteins. Also like clusterin, Hp lacks ATPase activity and has no
independent ability to refold misfolded proteins. The possibility that Hp holds
misfolded proteins in a state competent for refolding by other chaperones is currently
untested. Immunoaffinity depletion of Hp from human serum significantly increased
the amount of protein that precipitated in response to stresses (Yerbury et al., 2005).
Thus, Hp has the ability to protect many different proteins from stress-induced
amorphous precipitation and its effects in whole human serum suggest that this
activity is likely to be relevant in vivo. Currently, there are no published studies of the
effects of Hp on amyloid formation, although Hp is found associated with amyloid
deposits in vivo (Table (1)).
When complexed to Hb, Hp is known to bind to the CD163 cell surface receptor
(Graversen et al., 2002). Other receptors to which Hp alone binds are the
CD11b/CD18 integrin (Mac-1/CR3), which also binds denatured proteins and the
iC3b fragment of complement (Ross 2000), and the CD22 B lymphocyte receptor.
Unidentified specific Hp binding sites have also been reported to occur on neutrophils
(Oh et al., 1990) and mast cells (El-Ghmati et al., 2002). Thus, it appears feasible that
Hp might interact with one or more of these receptors to mediate the clearance and
degradation of misfolded extracellular proteins.
3.3 α 2-Macroglobulin (α2M)
α2-Macroglobulin (α2M) is a major human blood glycoprotein, comprised of ~10%
carbohydrate by mass. It is assembled from four identical 180 kDa subunits into a 720
kDa tetramer; the 180 kDa subunits are disulphide bonded to form dimers, which noncovalently interact to yield the final tetrameric quaternary structure (Jensen and
Sottrup-Jensen 1986). α2M is present in human plasma and CSF at 1500-2000
(Sottrup-Jensen 1989) and 1-3.6 µg/ml (Biringer et al., 2006), respectively. It has a
well known ability to inhibit a broad spectrum of proteases, which it accomplishes
using a unique trapping method. When exposed to a protease, α2M undergoes limited
proteolysis at its bait region leading to a large conformational change, physically
trapping the protease within a steric “cage” (Sottrup-Jensen 1989). The trapped
protease forms a covalent linkage with α2M by reacting with an intramolecular thiol
ester bond to yield a conformationally altered form known as “activated” or “fast”
α2M (α2M*), which exposes a receptor recognition site for low density lipoprotein
receptor related protein (LRP) (Sottrup-Jensen 1989). By directly interacting with the
thiol ester bond, small nucleophiles such as methylamine can also activate α2M
(Imber and Pizzo 1981).
Aside from its interactions with proteases, α2M binds to Aβ peptide and β2microglobulin, which are associated with Alzheimer’s disease (Narita et al., 1997)

and dialysis related amyloidosis (Motomiya et al., 2003), respectively, to cytokines
and growth factors (Mettenburg et al., 2002), and to a range of hydrophobic
molecules including endotoxin, phenyl-Sepharose, and liposomes (Barrett 1981). The
binding to hydrophobic molecules does not inhibit the trapping of proteases and is not
known to be associated with any conformational changes (Barrett 1981). Previous
work has indicated that α2M-polypeptide complexes are immunogenic (Chu and
Pizzo 1993; Binder et al., 2001). α2M bound peptides are internalised by LRP and
fragments of the peptide are subsequently re-presented on the cell surface. This
response is identical to the one elicited by peptides chaperoned by intracellular heat
shock proteins (Srivastava 2002). A further hint that α2M might have chaperone
properties came from the observation that it inhibits the aggregation of Aβ and
protects cells from Aβ toxicity (Du et al., 1997). It was recently shown that α2M has a
promiscuous ATP-independent chaperone action similar to that of both clusterin and
haptoglobin. It forms stable complexes with misfolded proteins to inhibit their stressinduced aggregation and precipitation but is unable to independently effect their
refolding (French et al., 2007). α2M is the first known mammalian protein with both
protease inhibitor and chaperone-like activities.
Selective removal of α2M from whole human serum renders proteins in this fluid
more susceptible to precipitation, even at 37 oC (French et al., 2007), suggesting that
the in vitro chaperone properties of α2M are likely to be relevant in vivo. The effects
of clusterin, haptoglobin and α2M on plasma protein precipitation are additive
(French et al., (2007) and unpublished data), suggesting that even though they are
promiscuous in their interactions with different substrate proteins, the ECs may provide
complementarity with respect to the endogenous extracellular proteins they protect.
Interaction with a misfolded substrate protein does not activate α2M and the resulting
complex is not bound by LRP. However, if the complex subsequently interacts with
and traps a protease, then the activated conformation is adopted and the
α2M/protease/misfolded protein complex is bound by LRP (French et al., 2007). Thus,
for example, interaction with abundant proteases at sites of inflammation may be one
in vivo switch to trigger LRP-mediated uptake of α2M/misfolded protein complexes.
Although LRP is the only known receptor for α2M, it remains possible that nonactivated α2M/misfolded protein complexes are taken up via other currently unknown
cell surface receptors. Like the other ECs, it has been proposed that α2M patrols
extracellular spaces for misfolded proteins and facilitates their disposal via receptor
mediated cellular uptake. This activity would contribute to important antiinflammatory actions of α2M in vivo.
3.4 Serum amyloid P component
SAP is a member of the pentraxin family of proteins which are characterised by five
identical subunits noncovalently associated to form a disc-like structure. The SAP
pentamer consists of five 25 kDa subunits each containing 204 amino acids and a
single intra-chain disulfide bond, and constructed from multiple anti-parallel β-strands
arranged in two sheets (Emsley et al., 1994). Each human SAP subunit bears an
invariant N-linked biantennary oligosaccharide which constitutes more than 8% of the
mass of the molecule (Pepys et al., 1994). It has been proposed that SAP circulates as
a decamer with two pentameric discs noncovalently bound face to face (Wood et al.,
1988; Emsley et al., 1994). Other reports claim that SAP exists as a single pentamer

in the body and that the decameric form is obtained only upon purification (Sorensen
et al., 1995; Aquilina and Robinson 2003). SAP is synthesised and catabolized in the
liver, and is present in human plasma and CSF at concentrations of ~ 40 µg/mL
(Hutchinson et al., 1994) and 8.5 µg/ml (Hawkins et al., 1994), respectively. Whereas
SAP is an acute-phase protein in mice (Pepys et al., 1979), in humans it's plasma
concentration is not significantly elevated during acute inflammation (Pepys et al.,
1978).
Each subunit monomer has two Ca2+-binding sites and shows Ca2+-dependent binding
to many different ligands, including certain oligosaccharides, glycosaminoglycans
(Hamazaki 1987), fibronectin (de Beer et al., 1981), C-reactive protein (Swanson et
al., 1992), aggregated IgG (Brown and Anderson 1993), C1q (Sorensen et al., 1996),
complement C4-binding protein (Sorensen et al., 1996), DNA (Pepys and Butler
1987), chromatin (Breathnach et al., 1989), histones (Hicks et al., 1992), and
phosphoethanolamine-containing compounds such as phosphatidylethanolamine
(Emsley et al., 1994). Interaction with these ligands localises SAP to elastic
microfibrils (Breathnach et al., 1981), glomerular and alveolar basement membrane,
arterioles, bronchioles, sarcolemma of cardiac and smooth muscle (Dyck et al., 1980),
and all forms of amyloid (Pepys et al., 1979).
Previous studies of the chaperone properties of SAP are insufficient in number and
depth to allow unequivocal classification of SAP, together with clusterin, haptoglobin
and α2M as a genuine EC. However, one study showed that when added to a refolding
buffer containing denatured lactate dehydrogenase (LDH), SAP markedly enhanced
the yield of active LDH. The reaction was supra-stoichometric, as a ratio of SAP
pentamer to LDH substrate of 10:1 was needed to recover 25% of enzyme reactivity
(Coker et al., 2000). This suggests that SAP is an inefficient refolding-competent
chaperone. It is important to note that this in vitro activity was demonstrated in the
absence of ATP and any "helper" chaperones. Clearly, further studies of the
chaperone properties of SAP and how they might relate to known ECs will be
valuable. Of particular interest in the current context, SAP has been found present in
all amyloid deposits examined (Breathnach et al., 1981; Coria et al., 1988; Kalaria et
al., 1991; Yang et al., 1992). The interaction between SAP and amyloid fibrils is
highly specific, and the abundance of SAP in amyloid fibrils relative to its trace
concentration in plasma is extraordinary (Botto et al., 1997). SAP has a proteaseresistant β-pleated sheet structure that in the presence of Ca2+ is resistant to
proteolysis (Kinoshita et al., 1992). Furthermore, it has been shown that SAP inhibits
the degradation of several types of amyloid fibrils by proteases. Tennent et al. (1995)
suggested that SAP protects amyloid from proteolytic degradation in vivo by binding
to fibrils and masking fibrillar conformation.
4.0 THE EFFECTS OF EXTRACELLULAR CHAPERONES ON AMYLOID
FORMATION AND TOXICITY
4.1 Effects of ECs on amyloid formation in vitro
In vivo amyloid formation and deposition is, in terms of its nature, onset, and
progression, an extraordinarily complex process that can occur over much of the
lifetime of an individual, thus making it difficult to monitor and study over a
reasonable timescale. The co-deposition of other components, including proteins (e.g.
molecular chaperones), metals, and glycosaminoglycans, adds further complexity to

the situation. Such complexity prevents the amyloid-forming process from being fully
reproduced in a test tube. Nevertheless, by examining indvidual steps in the process in
vitro, it is still possible to gain insight into many facets of in vivo amyloid formation
and deposition. In vitro, conditions can be manipulated such that fibril formation can
be assessed in a manageable timeframe. Perturbation of the environment, with the
specific aim of increasing the population of aggregation-prone intermediates, is a
common strategy that usually involves, but is not limited to, the use of polypeptide
concentrations that exceed physiological levels, alterations to pH or ionic strength, the
use of denaturants, or incubation at high temperatures. Much of the current
knowledge regarding the effects of ECs on amyloid formation has been gleaned from
in vitro studies that utilise such strategies.
The in vitro chaperone actions of clusterin, haptoglobin, α2M, and SAP, have been
previously reported (see section 3.0). Whilst many studies have highlighted the ability
of these EC to suppress amorphous aggregation, their effects on amyloid formation
are, apart from clusterin, less well-documented. A report published in 1994 provided
the first indication that clusterin is capable of preventing amyloid fibril formation
(Oda et al., 1994). In this report, it was shown that the formation of Aβ fibrils could
be inhibited by sub-stoichiometric levels of clusterin, a finding which has since been
confirmed by other independent studies (Matsubara et al., 1996; Hughes et al., 1998).
Since then, clusterin has been shown to potently inhibit, in a dose-dependent manner,
the formation of fibrils derived from a broad range of other unrelated ‘substrates’,
including prion protein Pr106-126 (McHattie and Edington 1999), Apo C-II (Hatters et
al., 2002), chicken egg white lysozyme, calcitonin, κ-casein, α-synuclein, β2microglobulin, PI3-SH3, Aβ, a model peptide CCβw (Yerbury et al., 2007), and the
naturally occurring amyloidogenic variant of lysozyme, I56T (Kumita et al., 2007).
Similar inhibitory capabilities have also been documented for α2M. Like clusterin,
sub-stoichiometric levels of α2M (at a 1:8 molar ratio of α2M:substrate) were enough
to completely inhibit the formation of fibrillar Aβ aggregates (Hughes et al., 1998).
Finally, it was shown that in vitro a 1:5 molar ratio of SAP to target protein
completely attenuated the fibrillation of Aβ1-42 and α1-antitrypsin-derived C-terminal
peptides (Janciauskiene et al., 1995). There are no published data to show whether
haptoglobin has similar anti-amyloidogenic properties in vitro.
The ability of sub-stoichiometric levels of clusterin, α2M, or SAP to inhibit
fibrillogenesis suggests that the substrate species involved is not highly populated but
is crucial for fibril formation. Studies probing the mechanisms of clusterin's
chaperone action have provided some indications as to the identity of such species.
Recent studies exploring the interactions between clusterin and amyloid forming
proteins revealed that clusterin did not bind to the native form of the substrates tested,
nor did it interact with mature fibrils (Kumita et al., 2007; Yerbury et al., 2007).
Interestingly, the greatest amount of anti-amyloidogenic effect afforded by clusterin
was detected when it was present during the early stages of fibrillogenesis. Yet, based
on results obtained by mass spectrometry, the presence of clusterin did not eliminate
the appearance of a partially unfolded monomeric intermediate identified as the initial
step in the pathway of lysozyme amyloidosis (Kumita et al., 2007). The addition of
clusterin during the elongation phase did not greatly alter the kinetics of aggregation
of I56T lysozyme (Kumita et al., 2007). Similarly, clusterin was more effective at
suppressing fibril formation in solutions of Aβ and SH3 which had been seeded with

samples taken from corresponding aggregation mixtures during the lag phase
compared with those taken from the late (plateau) phase (Yerbury et al., 2007). This
is consistent with data showing that at the same molar clusterin:substrate ratio, as the
concentration of amyloid forming protein is increased, clusterin is less able to inhibit
the formation of amyloid by Apo C-II, PI3-SH3 and Aβ. The increased concentration
of amyloid forming protein increases the abundance of destabilised monomer,
favouring self-association into oligomers able to nucleate the aggregation process and
thereby shortening the lag phase (Hatters et al., 2002; Yerbury et al., 2007).
Taken together, the above results suggest that clusterin primarily exerts its effects on
amyloid formation at or near the nucleation stage. It is likely to be a destabilized prefibrillar oligomeric species that are targets for binding by clusterin. During amyloid
formation, conformationally rearranged proteins and oligomeric species are usually
present at concentrations low enough to account for the potent sub-stoichiometric
effects of the ECs; when in equilibrium with the native fold, destabilised and nonnative structures can initiate aggregation when present at an abundance as low as 1%
(Canet et al., 2002; Marcon et al., 2005). The binding of ECs such as clusterin and
α2M probably reduces the availability of these species to participate in the nucleation
events that normally precedes fibril formation (Fig. (2)).
The broad-range specificity of clusterin for amyloid forming substrates is not only
impressive but suggests that the effects of clusterin on amyloid formation may be
generic. This suggests that there may be a structural feature common amongst
amyloid-forming peptides and proteins that are specifically recognised by the
chaperone. Whether this is also true for other ECs is not known. Nevertheless, under
experimental conditions that favour the formation of amorphous aggregates, both
clusterin and α2M have been shown to form high molecular weight complexes with
denatured proteins, at least in part, through hydrophobic interactions (section 3.1 and
French et al., (2007)).
Given that hydrophobicity is considered to be an important universal determinant in
the formation of fibrillar protein aggregates (Chiti et al., 2002), it is therefore feasible
that the inhibitory effects of clusterin, α2M, and SAP on in vitro amyloid formation
can be attributed to similar hydrophobic interactions between the chaperones and their
amyloidogenic substrates. In support of this notion, clusterin and α2M (activated and
non activated) seem to preferentially bind intermediate protein species formed during
amyloid-related aggregation but do not bind to native structures of the same proteins
(Narita et al., 1997; Lauer et al., 2001; Hatters et al., 2002; Mettenburg et al., 2002;
Kumita et al., 2007; Yerbury et al., 2007). Five times more clusterin-Aβ complex was
formed when clusterin was incubated for 18 h at 37oC with Aβ monomer than was the
case when it was incubated under the same conditions with pre-aggregated Aβ
(Matsubara et al., 1995). Similarly, α2M did not initially form complexes with Aβ but
under conditions that promote amyloid formation stable α2M-Aβ complexes were
formed after 2 hours (Narita et al., 1997). This pattern of binding may be explained
by the different levels of hydrophobicity exposed on the various protein
conformations produced at different stages of the amyloid-forming pathway. For
example, the level of exposed hydrophobicity on a native protein is generally low
with hydrophobic residues buried inside the molecule. However, after the protein has
been destabilized some of the originally buried hydrophobic residues will become

accessible to the solvent and perhaps chaperones. Subsequent protein aggregation will
again bury most of the hydrophobic residues inside the aggregating structure.
The relationship between α2M and Aβ is complex due to its two functional
conformations. There is no doubt that α2M binds to Aβ with high affinity. However,
there are conflicting reports of the particular α2M conformations that bind to Aβ.
There are several reports claiming that Aβ binds to active α2M but not to native α2M
(Narita et al., 1997; Lauer et al., 2001; Mettenburg et al., 2002). In contrast, others
claim that native α2M binds to Aβ (Du et al., 1997; Hughes et al., 1998). Moreover,
native α2M can inhibit fibril formation (Du et al., 1997; Hughes et al., 1998),
providing additional evidence that α2M in its native state can bind Aβ. The binding of
Aβ occurs in a site that is distinct from the protease and growth factor binding sites
(Mettenburg et al., 2002). It is most probable that the binding occurs to a linear
sequence of amino acids, as both activated and native α2M bind Aβ after they have
been denatured (Mettenburg et al., 2002). In a curious combination of functions,
activated α2M seems to be able to feed Aβ inside its “cage” to facilitate its proteolysis
by a trapped protease (Qiu et al., 1996; Lauer et al., 2001).
Despite many reports of the ability of ECs to inhibit fibril formation in vitro, there are
indications to suggest that they may, at least under certain conditions, actually
promote the formation or maintain the persistence of amyloid fibrils. α2M binds to
and protects prion protein from degradation by proteinase K; this protection was not
exerted by α2M binding to and inhibiting proteinase K (Adler and Kryukov 2007). In
addition, another study showed that α2M prevents the trypsin-mediated degradation of
fibrils composed of either immunoglobulin lambda (λ) light chains or β2M (GouinCharnet et al., 1997). Similarly, the calcium-dependent binding of SAP to amyloid
fibrils formed from Aβ, serum amyloid A protein or immunoglobulin light chain,
protected the fibrils from subsequent protease-mediated degradation (Tennent et al.,
1995). This in turn led to suggestions that SAP may promote the persistence of
amyloid deposits in vivo.
For some protein substrates, at low clusterin:substrate ratios (1:50-1:500), clusterin
promotes the formation of aggregates with an increased level of thioflavin T
fluorescence, suggesting that (at these ratios) it promoted the formation of fibrils from
calcitonin, α-synuclein and Aβ. At these low levels, clusterin was found incorporated
into insoluble Aβ and SH3 fibrils (Yerbury et al., 2007). Similarly, at low SAP:Aβ
ratios, SAP promoted the formation of Aβ aggregates (Hamazaki 1995); at SAP:Aβ
of 1:1000, short fibrillar-like structures lacking typical amyloid features were formed
which often contained associated SAP molecules (Janciauskiene et al., 1995). In
addition, α2M has been shown to stabilize a conformation of the prion protein
resistant to proteinase K (PrPRes) that is thought to initiate aggregation and is
associated with prion disease pathology (Adler and Kryukov 2007). Taken together,
these results suggest that when ECs are present at low levels relative to the substrate
they may act to stabilize an otherwise unstable conformation and facilitate amyloid
fibril formation (Fig. (3)).
4.2 The in vitro effects of ECs on amyloid toxicity
Recent studies have indicated that the location of amyloid deposits in vivo do not
correlate well with sites of neurotoxicity (e.g. in AD (Kirkitadze et al., 2002), ALS

(Lee et al., 2002), Parkinson’s disease (Volles and Lansbury 2003) and familial
amyloidotic polyneuropathy (Sousa et al., 2001)). Neuronal losses associated with
these disorders may be brought about by toxicity exerted by smaller soluble
aggregates (sometimes referred to as oligomers or protofibrils; see section 2.2) (Chiti
and Dobson 2006). These protofibrils have been shown to be more toxic than both the
protein/peptide from which they are made and mature fibrils constructed from them
(Bucciantini et al., 2002). If this scenario is correct, then it follows that at least under
some conditions EC-mediated inhibition of protein aggregation in the brain could
actually promote neurotoxicity. When tested against neuronal cell lines, under certain
specific conditions, clusterin and α2M were shown to promote the neurotoxicity of
Aβ (clusterin - PC12 cells (Oda et al., 1995); α2M - LAN5 cells (Fabrizi et al., 2001)).
In stark contrast, using primary rat mixed neuronal cultures, others have demonstrated
that clusterin and α2M can protect cells from Aβ toxicity (Boggs et al., 1996; Du et
al., 1997). Even within individual studies, depending on the conditions used, clusterin
was shown both to protect cells and to promote cytotoxicity. Complexes of clusterin
and Aβ formed at high ratios of clusterin:Aβ (e.g. 1:10) were less toxic to SH-SY5Y
cells than Aβ alone; in contrast, complexes formed at low ratios of clusterin:Aβ (e.g.
1:500) were more toxic than Aβ alone (Yerbury et al., 2007). Thus, the effects of ECs,
and in particular clusterin, on the toxicity of aggregates are complex and have been
shown to depend upon the clusterin:substrate ratio, the stage of amyloid formation at
which the aggregates are formed, and the cell type.
It has been postulated that the level of hydrophobicity exposed by aggregates may
determine their toxicity (Chiti and Dobson 2006). How this directly relates to the
mechanism of their toxicity is uncertain and is currently a hotly researched topic, but
it is probably due to interactions of hydrophobic residues with membranes or other
molecules essential for normal cellular function (Chiti and Dobson 2006). This, in
part, may explain the differential effects of clusterin on toxicity. When the substrate
protein is present at a high molar excess, clusterin may be unable to mask all regions
of exposed hydrophobicity but instead may stabilize aggregates which retain
sufficient exposed hydrophobicity to exert toxicity (Fig. (3)). In contrast, at higher but
still sub-stoichiometric ratios of clusterin:Aβ, toxicity is reduced (Yerbury et al.,
2007).
Another potentially important factor to consider when trying to understand the in vivo
effects of ECs on amyloid toxicity, is that in addition to their effects on the nature and
size of protein aggregates, ECs may also be involved in the physical clearance of
protein aggregates. This is illustrated by the demonstration that in the presence of
α2M (but not otherwise), SH-SY5Y cells expressing the α2M receptor (LRP) are more
resistant to Aβ toxicity than cells that do not (Fabrizi et al., 2001). The protective
effect of α2M could be inhibited by RAP (a pan-specific inhibitor of LRP ligand
binding). Furthermore, α2M promoted Aβ toxicity against LRP-negative LAN5 cells
but had the opposite effect with LRP-expressing LAN5 transfectants (Fabrizi et al.,
2001). Therefore, although ECs may provide cells with some protection by binding to
exposed hydrophobic regions on protein aggregates, a further protective mechanism
may only come into play when appropriate cell surface receptors are available to
mediate uptake and degradation of EC-substrate protein complexes.
4.3 ECs and protein disposal in the brain

It has been proposed that ECs are scavengers for hydrophobic proteins in the
extracellular space, inhibiting protein aggregation and deposition and guiding
misfolded proteins to specific receptors for their internalization and subsequent
lysosomal degradation ((Yerbury et al., 2005) and see Fig. (3)). This system of EC
directed receptor-mediated endocytosis may play a major role in the maintenance of
protein solubility in the extracellular fluids in the brain (interstitial fluid and CSF).
Evidence supporting this model includes:
(1) In the CNS, ECs are produced locally in astrocytes and some neuron populations
(Lauro et al., 1992; Zwain et al., 1994; Klimaschewski et al., 2001) and can be
transported from plasma across the blood brain barrier (BBB) (Zlokovic 1996). The
receptors LRP and megalin are expressed on the surface of cells in contact with CSF
(i.e. chloroid plexus and ependymal cells (Kounnas et al., 1994) and at the BBB
(Zlokovic 1996; Donahue et al., 2006) and LRP is also found on the surface of
astrocytes (Arelin et al., 2002) and microglial cells (Laporte et al., 2004).
(2) Clusterin and α2M are both found complexed with soluble amyloid-forming
proteins in human CSF (Ghiso et al., 1993; Adler and Kryukov 2007).
(3) It has previously been shown that clusterin-Aβ complexes bind to megalin on the
surface of mouse teratocarcinoma F9 cells, and are subsequently internalised,
transported to lysosomes and degraded (Hammad et al., 1997). Similarly, α2M-Aβ
complexes are internalized via LRP expressed on U87 cells and are subsequently
degraded (Narita et al., 1997).
(4) The normally rapid removal of radiolabelled Aβ from mouse brain is significantly
inhibited by the LDL family inhibitor RAP and antibodies against LRP-1 and α2M
(Shibata et al., 2000). Furthermore, when complexed with clusterin, the rate of
clearance of Aβ1−42 from the mouse brain across the BBB into plasma is increased by
more than 80% and this transport is significantly inhibited by anti-megalin antibodies
(Bell et al., 2007).
4.4 When quality control is compromised?
If a system of extracellular protein quality control (QC) operates and is efficient, why
do protein deposits sometimes develop? Protein aggregation in the brain is generally
age-related, and some proteins such as Aβ accumulate as a part of normal aging
(Fukumoto et al., 1996). In young, healthy humans the disposal of proteins such as
transthyretin or peptides like Aβ is efficient (that is there are no apparent protein
deposits). Thus, it is likely that protein deposition may represent an age-dependent
overloading of the QC system that ultimately results in toxicity and
neurodegeneration. If the QC system is overloaded in amyloid diseases of the brain, it
is critical to pinpoint the factors and pathways involved to facilitate identification of
new potential therapeutic strategies.
One poorly understood pathway relates to the observation that under some conditions
ECs can actually promote the formation of amyloid fibrils; clusterin, α2M and SAP
have been shown to promote fibril formation in vitro (Hamazaki 1995; Adler and
Kryukov 2007; Yerbury et al., 2007) (see section 4.1). In addition, in a transgenic
mouse model expressing APP (PDAPP mice), a comparison of clusterin -/- and
clusterin +/+ mice showed no difference in the amount of Aβ deposited in the brain,
however the amount of thioflavin S positive material was larger in clusterin +/+ mice
(DeMattos et al., 2002). Although there was no electron microscopy data to confirm
that this was in fact amyloid fibrils, the authors suggest that this demonstrates

clusterin promoted fibril formation in this model. In contrast, PDAPP apoE−/−,
clusterin−/− mice had significantly increased Aβ levels in CSF and intersititial fluid
and thioflavin–S deposits in the brain (DeMattos et al., 2004). The results of this
latter study were interpreted as suggesting that clusterin works cooperatively with
ApoE to inhibit the formation of Aβ amyloid in the brain. The interpretations
presented from these two studies are seemingly contradictory, and a clear
understanding of the in vivo role of clusterin in amyloidogenesis has yet to be
achieved. An important factor influencing the nature of the effect of clusterin on
amyloid formation, at least in vitro, is the clusterin:substrate protein ratio. At very low
ratios of clusterin:substrate, clusterin has been shown to enhance amyloid associated
thioflavin T fluorescence suggesting that it increases amyloid formation, while at
higher but still sub-stoichiometric ratios have the opposite effect (see section 4.1). A
similar biphasic effect on amyloid formation has also been shown for the intracellular
yeast chaperone hsp104 (Shorter and Lindquist 2004).
It is possible that at times in local microenvironments of the CNS, the concentrations
of ECs are low and that under these conditions they actually promote the formation of
amyloid fibrils. Interestingly, under conditions of high substrate protein excess,
clusterin becomes incorporated into insoluble aggregates (Yerbury et al., 2007).
Sequestration of clusterin into deposits would effectively lower it's availability, and
potentially further promote fibril formation. If the other ECs behave similarly, then it
is no surprise that all are found associated with plaques (see Table (1), and Fig. (3)).
In humans with AD (Duguid et al., 1989; May et al., 1989) and Creutzfeldt Jacob
disease (Duguid et al., 1989; Sasaki et al., 2002) the levels of clusterin mRNA are
increased, however, there is no associated increase in clusterin protein levels in AD
CSF (Lidstrom et al., 2001) and the level of clusterin protein in CSF is decreased by
2.5 fold in Creutzfeldt Jacob disease (Piubelli et al., 2006). In addition, decreased
levels of clusterin in the eye are thought to be responsible for deposition of Pseudo
exfoliation (PEX) material in PEX syndrome (Zenkel et al., 2006) (again clusterin is
found associated with PEX deposits).
Another factor that could favour the development of amyloid pathology is a
dysfunction in the expression or function of relevant cell surface receptors (see Fig.
(3)). Under some conditions, ECs may stabilize toxic conformations of substrate
proteins with exposed hydrophobicity (see section 4.2). If receptor-mediated
clearance is inadequate, the persistence of such toxic complexes could manifest as
neuronal damage. In vitro assays demonstrated that when neuronal cells were in
mixed cultures with astrocytes and microglia (which express receptors capable of
specifically binding to ECs, e.g. LDLR family members), by complexing with Aβ,
both clusterin and α2M were neuroprotective. However, when neuronal cells were
cultured alone, complexes of clusterin or α2M with Aβ were neurotoxic, suggesting
that complexes of EC and aggregating protein may be toxic in the absence of receptor
mediated endocytosis pathways. Moreover, there are increased plasma concentrations
of several LRP ligands in AD patients, including ApoE, α1 anti-chymotrypsin and
urokinase (Aoyagi et al., 1992; Licastro et al., 1995; Taddei et al., 1997) suggesting
that LRP may be either overwhelmed, downregulated or faulty in AD. More recently,
this has been confirmed by data showing that LRP expression at the BBB is decreased
in AD patients and mouse models (Deane et al., 2004). As discussed above (section
4.3), this is consistent with the results from mouse models where antibody-mediated

blockade of megalin and LRP significantly prolonged the time taken to clear Aβ from
the brain (Shibata et al., 2000; Bell et al., 2007).
5.0 CONCLUSION & FUTURE DIRECTIONS
In recent years there has been considerable progress in our understanding of protein
deposition disorders. In particular our understanding of the nature and significance of
amyloid formation and deposition and the role that these play in disease has taken
dramatic leaps forward. Further advances in understanding of the mechanisms which
control extracellular protein folding are likely to identify new strategies for effective
disease therapies. This chapter focused on what little is known about quality control
of the folding of amyloid forming proteins in the extracellular space of the brain.
Since the EC field is still in its infancy, this chapter is necessarily speculative in a
number of areas. However, it is quite clear that amyloid forming proteins such as Aβ
and prion proteins are ‘chaperoned’ in the brain by what have become termed
extracellular chaperones. It is proposed that once bound to misfolded proteins,
extracellular chaperones guide them to specific receptors that function to direct
proteins into lysosomes for degradation. In this scenario, specific receptors such as
LRP and megalin are an integral and critical part of a quality control system which
provides protection against dangerously hydrophobic proteins/peptides in the brain.
Since relatively little is known about ECs and their role in protein deposition diseases
many future directions are possible. Initially, it will be important to better understand
the mechanism by which, under some conditions, ECs promote amyloid formation, as
this has clear relevance to the development of any EC-based therapies. Certainly, it
will be critical to evaluate the roles of ECs in a variety of in vivo models of protein
deposition diseases. It may be possible to accelerate the pace of advances by utilizing
innovative new disease models such as those developed using the fruit fly Drosophila.
The short generation times and ease of genetic manipulation in these models create
opportunities not accessible with mammalian systems. Much remains to be discovered,
ensuring that exciting times lie ahead.

Table 1. Summary of protein deposition disorders in the CNS and the extracellular chaperones known to be associated with them.
Disease

Aggregating protein/peptide

Location

EC associated with deposit

Alzheimer’s disease

Aβ peptide

Extracellular

Spongiform encephalopathies

Prion Protein

Extracellular

Parkinson’s disease

α-synuclein

Intracellular

Dementia with lewy bodies

α-synuclein

Intracellular

Clus (Sasaki et al., 2002), SAP (Kalaria and Grahovac 1990)

Frontotemporal dementia with Parkinsonsism

Tau

Intracellular

Unknown

Amytrophic lateral sclerosis

Superoxide dismutase 1

Intracellular

Unknown

Huntington’s disease

Huntingtin with poly Q expansion
Ataxins with poly Q expansion

Intracellular
Intracellular

Unknown
Unknown

Spinal and bulbar muscular atrophy

TATA box-binding protein with poly Q expansion
Androgen receptor with poly Q expansion

Intracellular
Intracellular

Unknown
Unknown

Hereditary dentatorubral-pallidoluysian atrophy

Atrophin-1 with poly Q expansion

Intracellular

Unknown

Familial British dementia

ABri

Extracellular

Clus (Ghiso et al., 1995), SAP (Rostagno et al., 2007)

Familial Danish Dementia

ADan

Extracellular

Clus (Lashley et al., 2006), SAP (Rostagno et al., 2007)

Familial amyloid polyneuropathy

TTR

Extracellular

Unknown

Age related macular degeneration

Drusen components

Extracellular

Clus (Sakaguchi et al., 2002), SAP (Ambati et al., 2003)

Gelatinous drop-like corneal dystrophy

Keratoepithelin

Extracellular

Clus (Nishida et al., 1999), SAP (Stix et al., 2005)

Lattice type I corneal dystrophy

M1S1

Extracellular

Clus (Nishida et al., 1999), SAP (Stix et al., 2005)

Pseudoexfoliation (PEX) syndrome

PEX components

Extracellular

Clus (Zenkel et al., 2006), SAP (Schlotzer-Schrehardt et al., 1992)

Down’s syndrome

Aβ

Extracellular

Clus (Kida et al., 1995), SAP (Kalaria and Grahovac 1990)

Clus (Calero et al., 2000), α2 M (Fabrizi et al., 2001), Hp (Powers
et al., 1981), SAP (Perlmutter et al., 1995)
Clus (Chiesa et al., 1996; Freixes et al., 2004), α2M (Adler and
Kryukov 2007), SAP (Ishii et al., 1984)
Clus (Sasaki et al., 2002), SAP (Kalaria and Grahovac 1990),
α2M(Nicoletti et al., 2002)

Spinocerebellar ataxia’s

Figure 1. A schematic representation of some of the fates that await polypeptide
chains in vivo. Newly synthesized polypeptides fold into their biologically active,
native conformation, often via the transient formation of one or more partially
unfolded intermediates. Failure to do so may result in the polypeptide experiencing
other fates, including degradation or irreversible aggregation to form either disordered
(amorphous) aggregates or highly organized amyloid fibrils. The formation of
amyloid fibrils occurs via a nucleation dependent mechanism in which soluble
prefibrillar oligomers or nuclei are formed during the lag phase. These oligomeric
species then act as templates to sequester other aggregation-prone intermediates,
leading to rapid fibril growth (represented by the exponential elongation phase) and
subsequently, to the formation of insoluble mature amyloid fibrils. The plateau phase
represents the steady state when maximum fibril growth has been reached. Adapted
from (Chiti and Dobson 2006).
Figure 2. Possible consequences for proteins when extracellular quality control
mechanisms fail. An extracellular quality control process has recently been proposed
whereby extracellular chaperones (EC) facilitate the clearance of non-native protein
structures via receptor-mediated endocytosis and intracellular, lysosomal degradation.
The existence of such a quality control mechanism ensures that proteins do not persist
beyond their intended lifespan in the extracellular space. Failure of this system, at any
of its stages, may potentially result in the onset of disease caused by the accumulation
and/or deposition of i) cytotoxic species generated through the amyloid assembly
pathway, ii) aberrantly folded structures and aggregates such as insoluble complexes
of ECs and fibrillar material, or iii) degradation-resistant complexes (as exemplified
by Aβ1-42 amyloid fibrils).
Figure 3. The biphasic effects of chaperones on amyloid fibril formation. Under
certain conditions, proteins readily self-associate into highly structured amyloid fibrils.
The kinetics of the amyloid assembly process is often depicted as a sigmoidal curve to
reflect the three distinct phases (i.e. lag, elongation and plateau; see also Figure 1) that
characterizes the fibril formation pathway. This kinetic profile can be detected in vitro
using real-time spectroscopic techniques, such as those that monitor fibril formation
by measuring the relative binding of amyloid-specific dyes such as Congo-red and
Thioflavin T. Such techniques have, in the past, provided clues as to what effects
chaperones have on fibril formation. Using various model substrate proteins, it was
shown that complete inhibition of fibril formation can be achieved when clusterin and
α2M are present at high (but usually still sub-stoichiometric) levels relative to the
substrate protein. Yet, at low EC:substrate ratios, extensive amyloid or amyloid-like
fibril formation is observed for some substrate proteins, suggesting that in these cases,
ECs may be stabilizing an otherwise unstable conformation and promoting amyloid
fibril formation
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